With structures similar to [177Lu]Lu-PSMA-617, PSMA-targeted RNT agents are an exhibition of the medical uses of therapeutic radionuclides, namely β- or α-emitters, in tandem with their imaging counterparts for precision prostate cancer treatment via the concept or strategy of theranostics. Here, FOLH1 is linked to prostate carcinoma.